Among over 151,000 patients, use of GLP-1 drugs was linked to a lower risk of death compared with no use (adjusted HR 0.77, ...

Patients with psoriatic arthritis who received GLP-1 receptor agonists exhibited lower risks for mortality and cardiovascular ...

Glucagon-like peptide 1 receptor agonists (GLP-1RA) have made waves as treatments for obesity and type 2 diabetes, but a new report suggests they might also have clinical benefits for certain patients ...

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and ...

Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type 2 ...

Patients with obesity and asthma who used GLP-1 receptor agonists had significantly fewer exacerbations and prednisone use ...

Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns ...

Observational data indicate that GLP-1 receptor agonists might be beneficial for kidney transplant recipients with diabetes. GLP-1 receptor agonists are associated with better kidney graft and ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for metabolic disorders, particularly type 2 diabetes and obesity. At the heart of ...